In a continuing study on the aetiology of Silver-Russell syndrome (SRS), we detected a patient with a heterozygous deletion in the growth hormone gene cluster (17q22-q24). The deletion of the chorionic somatomammotrophin hormone 1 (CSHl) gene was inherited from the patient's father. The patient shows typical symptoms of SRS. Though deletions of CSH1 have been reported without any phenotypic consequences, the heterozygous deletion might be involved in the aetiology of SRS in the case presented here. Apart from other observations in SRS, like maternal uniparental disomy 7, changes in the genomic region 17q22-qter might be responsible for the expression of this syndrome for at least some of the patients, leading to the heterogeneity of SRS. (JMed Genet 1998;35:784-786) 
Silver-Russell syndrome (SRS), a malformation syndrome characterised by pre-and postnatal growth retardation, has been described in more than 380 patients, most of them being sporadic cases.' The aetiology is not yet known. Even though a few patients with chromosomal abnormalities have been described, there is no uniform pattern of genetic abnormalities, apart from two SRS patients where the chromosomal region 17q25 was involved in chromosomal rearrangements.-Additionally, several patients with features similar to SRS and partial monosomy for distal 15q have been reported.4 Studies published previously describe maternal uniparental disomy for the entire chromosome 7 in almost 10% of the patients. [5] [6] [7] [8] The human growth hormone (GH) gene cluster is localised in the vicinity of the breakpoint 17q25 (17q22-q24). It To evaluate the number of SRS patients with genomic variations in the GH cluster, we screened 54 SRS families with a short tandem repeat marker (STR) located in this cluster. Further characterisation of the GH gene cluster was performed with a specific cDNA probe.
Case report
The patient was born at 30 weeks of gestation by caesarean section. Severe growth retardation was detected in the 23rd week by ultrasound. The operation was performed because of oligohydramnios and an acute deterioration of CTG. At birth, the infant had symmetrical growth retardation with a weight of 640 g (-3.9 SD"), a length of 32.5 cm (-3.4 SD), and a head circumference of 22.7 cm. The placenta was small with infarctions. The patient was the second child of a healthy mother. The first child was born prematurely after 28 weeks and died 10 days postnatally. The mother's height is within the normal range (161 cm, -0.6 SD), whereas the father is short (163 cm, -2.2 SD). The patient's motor development was slightly delayed and in childhood he had behavioural difficulties with hyperactivity. Myopia was diagnosed at the age of 2'/2 years and is not progressive. In infancy, the patient exhibited typical dysmorphic features of SRS with a large forehead and a small, asymmetrical face. Throughout infancy and childhood, severe growth failure continued. At the age of 71/2 years he had a height of 108.9 cm (-3.1 SD) and a weight of 14.7 kg (-2.8 SD); bone age was 5'/2 years (Greulich and Pyle Mo=mother, szes of all bands were normal, but both the Pat=patient.
patient's DNA and that of his father showed weaker intensities of the 5.3 kb band (CSH1). We conclude that the patient and his father are heterozygous for a deletion of CSH1. Digestion with HindIII confirmed this finding (not shown): the 14.8 kb band corresponding to CSH1 was weaker in the patient and his father than in controls. The other two bands, 21.3 and 25 kb, representing GH-V-CSH2 and GH-N-CSH-L, respectively, were normal. Taking the results of these tests together, we conclude that the deletion in the case presented here is within the 5.3 kb fragment of CSH1 and includes the coding region of CSH1 as well as the cAMP and the PMA responsive elements (-1102 to -1096) .
Alterations in the GH gene cluster have not so far been described in SRS patients. Inactivation of placental CSH and GH genes causes an abnormal biochemical phenotype, but it does not cause disease.'7 18 CSH concentrations in maternal serum increase linearly until about the 30th week and the rate of secretion is greater than that of any protein hormone. Reduced CSH secretion has been detected in different pathological conditions associated with abnormal fetal growth, including diabetes, pre-eclampsia, erythroblastosis, and intrauterine growth retardation. '9 In the mother the increase of serum IGF-I during pregnancy, which is a prerequisite for adequate nutrient supply to the fetus and normal fetal growth,20 is at least in part the result of the increasing CSH concentrations. In pregnancies associated with fetal homozygosity for deletion of the CSH genes, maternal IGF-I concentrations decline to values normally associated with hypopituitarism. Because of this, Grumbach et a!" suggested a role for CSH in supplying of nutrients to the fetus during maternal fasting. Although no direct effect of CSH deficiency on fetal growth has been shown so far,"7 18 recent experiments indicate that CSH may indirectly affect fetal tissue growth.'9 CSH stimulates amino acid transport and uptake and IGF production and there are diabetogenic and anabolic effects of CSH in different fetal tissues mediated by specific CSH receptors. 19 Additionally, it has been shown that in pathological pregnancies with intrauterine growth retardation CSH concentrations are reduced.22 In summary, CSH plays a pivotal role during pregnancy, but whether there is a relation between the heterozygous deletion in our patient and the observed intrauterine growth retardation remains unclear.
The paternally inherited heterozygous deletion of CSH1 we found might be an interesting finding in respect to the aetiology of intrauterine growth restriction and Silver-Russell syndrome, which to our present knowledge seems to be heterogeneous. Further analyses will show whether there are candidate genes or candidate gene clusters in the vicinity of the breakpoint 17q25 and whether CSH1 or functionally related factors are involved in the aetiology of SRS.
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